Review



high ca125 control sera  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Bio-Rad high ca125 control sera
    OC Test and <t>CA125</t> enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.
    High Ca125 Control Sera, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high ca125 control sera/product/Bio-Rad
    Average 92 stars, based on 18 article reviews
    high ca125 control sera - by Bioz Stars, 2026-05
    92/100 stars

    Images

    1) Product Images from "Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test"

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    Journal: The Journal of Molecular Diagnostics : JMD

    doi: 10.1016/j.jmoldx.2024.09.001

    OC Test and CA125 enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.
    Figure Legend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Clinical Proteomics

    Comparison of the Sensitivity of the OC Test and CA125 by Ovarian Cancer Histotype and Stage in the Verification Study
    Figure Legend Snippet: Comparison of the Sensitivity of the OC Test and CA125 by Ovarian Cancer Histotype and Stage in the Verification Study

    Techniques Used: Comparison

    OC Test and CA125 enzyme-linked immunosorbent assay performance in benign ovarian conditions. A and C: Training study EDTA plasma samples are shown. B and D: The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.
    Figure Legend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in benign ovarian conditions. A and C: Training study EDTA plasma samples are shown. B and D: The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Clinical Proteomics

    Comparison of the Performance of the OC Test and CA125 in Nonovarian Cancers and Inflammatory Conditions
    Figure Legend Snippet: Comparison of the Performance of the OC Test and CA125 in Nonovarian Cancers and Inflammatory Conditions

    Techniques Used: Comparison

    OC Test and CA125 enzyme-linked immunosorbent assay performance in nonovarian cancers and inflammatory conditions. A and C: Nonovarian (off-target cancer) samples are shown. B and D: The inflammatory condition samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.
    Figure Legend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in nonovarian cancers and inflammatory conditions. A and C: Nonovarian (off-target cancer) samples are shown. B and D: The inflammatory condition samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Techniques Used: Enzyme-linked Immunosorbent Assay

    Estimated Rates of False Positives due to Nonovarian Cancers if the OC Test or CA125 Was to Be Used for Screening an Average Risk Population
    Figure Legend Snippet: Estimated Rates of False Positives due to Nonovarian Cancers if the OC Test or CA125 Was to Be Used for Screening an Average Risk Population

    Techniques Used:



    Similar Products

    high ca125 control sera  (Bio-Rad)
    92
    Bio-Rad high ca125 control sera
    OC Test and <t>CA125</t> enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.
    High Ca125 Control Sera, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high ca125 control sera/product/Bio-Rad
    Average 92 stars, based on 1 article reviews
    high ca125 control sera - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    OC Test and CA125 enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics

    Comparison of the Sensitivity of the OC Test and CA125 by Ovarian Cancer Histotype and Stage in the Verification Study

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: Comparison of the Sensitivity of the OC Test and CA125 by Ovarian Cancer Histotype and Stage in the Verification Study

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: Comparison

    OC Test and CA125 enzyme-linked immunosorbent assay performance in benign ovarian conditions. A and C: Training study EDTA plasma samples are shown. B and D: The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in benign ovarian conditions. A and C: Training study EDTA plasma samples are shown. B and D: The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics

    Comparison of the Performance of the OC Test and CA125 in Nonovarian Cancers and Inflammatory Conditions

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: Comparison of the Performance of the OC Test and CA125 in Nonovarian Cancers and Inflammatory Conditions

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: Comparison

    OC Test and CA125 enzyme-linked immunosorbent assay performance in nonovarian cancers and inflammatory conditions. A and C: Nonovarian (off-target cancer) samples are shown. B and D: The inflammatory condition samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in nonovarian cancers and inflammatory conditions. A and C: Nonovarian (off-target cancer) samples are shown. B and D: The inflammatory condition samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: Enzyme-linked Immunosorbent Assay

    Estimated Rates of False Positives due to Nonovarian Cancers if the OC Test or CA125 Was to Be Used for Screening an Average Risk Population

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

    doi: 10.1016/j.jmoldx.2024.09.001

    Figure Lengend Snippet: Estimated Rates of False Positives due to Nonovarian Cancers if the OC Test or CA125 Was to Be Used for Screening an Average Risk Population

    Article Snippet: Blinded human plasma and serum samples as well as Lyphochek Tumor Marker Plus low, medium, and high CA125 control sera (catalog number 548X; Bio-Rad, Hercules, CA) were diluted 1:10 in 1× phosphate-buffered saline, pH 7.4 (Gibco catalog number 10010023; Thermo Fisher Scientific).

    Techniques: